# Treatment Options for Cystic Fibrosis
The treatment of cystic fibrosis focuses on three main areas: thinning and improving transport of the thick mucus in the lungs, preventing and fighting infections, and supporting overall health. In recent years, this treatment has changed significantly due to new medicines that work directly on the defective CFTR protein. This tab describes the different treatment groups that are used.
CFTR Modulators
These are medicines that try to repair or improve the function of the defective CFTR protein. They are divided based on what they do: 'correctors' and 'potentiators'.
**Ivacaftor** (a potentiator)
ProveniIncluded in official guidelines, or approved by EMA or FDA
Ivacaftor helps the CFTR protein open and close better, so that more salt and water can pass through the cell wall. It works particularly in certain genetic types of cystic fibrosis (especially gating mutations). The medicine is inhaled as a powder or taken as a tablet.
Known side effects are headache, vomiting and diarrhea. In some people, liver values rise temporarily. It is part of the official treatment guidelines and has been approved by the European Medicines Agency (EMA).
**Lumacaftor and ivacaftor in combination**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Lumacaftor is a corrector: it helps the defective CFTR protein take the right shape so it can work better. In combination with ivacaftor, this is used for a common genetic type (F508del-homozygous and certain heterozygous combinations). Tablet form.
Side effects include nausea, diarrhea and headache. Some patients feel tired or experience joint and muscle complaints. It requires extra monitoring effort because it can also affect other proteins in the body.
**Elexacaftor, tezacaftor and ivacaftor in combination** ('triple therapy')
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is a combination of two correctors (elexacaftor and tezacaftor) and a potentiator (ivacaftor). It works much stronger than the earlier combinations in common genetic types. Recent studies show that this combination leads to better lung function and fewer infections. Tablet form.
Side effects appear similar: vomiting, diarrhea, elevated liver values. This medicine is in the official guidelines and is EMA-approved. Research shows that it can help prevent pancreatitis and stabilize nutrition.
**Tezacaftor and ivacaftor**
ProveniIncluded in official guidelines, or approved by EMA or FDA
A combination of a corrector and potentiator for patients for whom triple therapy is not suitable or who previously received only this combination. Tablet form.
Side effects similar to other CFTR modulators. This medicine is used less now that triple therapy is available, but remains important for certain genetic types.
Medicines that thin mucus
**Dornase alfa** (DNase)
ProveniIncluded in official guidelines, or approved by EMA or FDA
This enzyme is inhaled and breaks down the complex DNA and proteins that make mucus thick. Dornase thins the mucus, so it can be coughed out of the lungs more easily. It is used daily or several times a week via a nebulizer.
Side effects are rare; sometimes throat complaints or vomiting. This remedy has been in the guidelines for thirty years and is considered standard.
**Hypertonic salt solution**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Salt water with a higher concentration than normal blood, inhaled as a mist. It draws water toward the mucus, making it thinner. Usually used several times a day. This is an inexpensive and safe supplement to dornase.
Side effects are minimal; sometimes a brief cough. This is one of the oldest treatments and is in all guidelines.
**Mannitol** (inhaled powder)
ResearchediPositive results in clinical studies, not yet standard treatment
A sugar substance that, like hypertonic salt, draws water toward the mucus and thins it. Inhaled in powder form. Research shows benefits for lung function in certain patients.
Side effects are usually minor; sometimes coughing or vomiting. It is used as a supplement, not as a replacement for dornase.
Infection control
**Inhaled antibiotics** (tobramycin, colistin, azithromycin)
ProveniIncluded in official guidelines, or approved by EMA or FDA
Because patients are vulnerable to serious lung infections caused by bacteria (especially Pseudomonas aeruginosa), antibiotics are regularly inhaled through nebulization. Tobramycin is given cyclically (28 days on, 28 days off). Colistin is a reserve antibiotic for resistant bacteria.
Side effects of inhaled antibiotics include tinnitus and hearing disorders (especially tobramycin; it should therefore be tested regularly), vomiting and sore throat. These medicines are listed in all infection control guidelines.
**Azithromycin** (as tablet or liquid)
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is not primarily for active infection, but for long-term inflammation and bacterial colonization. It is given in low doses and irregularly (for example three days per week) and works both as a bacterial inhibitor and an anti-inflammatory.
Side effects are nausea, diarrhea and abdominal cramps. This medicine is listed in many guidelines as standard background therapy.
Anti-inflammatory medicines
**Ibuprofen** (high doses)
ResearchediPositive results in clinical studies, not yet standard treatment
This anti-inflammatory agent can, in high doses, reduce the inflammatory response in the lungs. Studies from previous decades suggest that this may help slow the gradual decline of lung function.
Side effects of long-term use are stomach problems and kidney issues. This medicine is used less frequently since better medicines have become available.
Nutrition and supplements
**Supplements for fat-soluble vitamins** (A, D, E, K)
ProveniIncluded in official guidelines, or approved by EMA or FDA
Because the thick mucus in the pancreas does not break down intestinal fat well, patients can become deficient in vitamins that are only fat-soluble. These are therefore given regularly, often in adjusted amounts depending on blood values.
Side effects are rare at normal doses. This is standard care.
**Pancreatic enzymes**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many patients with cystic fibrosis have a poorly functioning pancreas (pancreatic insufficiency). They therefore receive replacement enzymes, usually as capsules with micro-granules, so that fat, proteins and carbohydrates can be broken down more effectively.
Side effects are rare. This is standard treatment for those whose pancreas is not functioning adequately.
Supportive care
**Physiotherapy and mucus-mobilizing techniques**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular physiotherapy, together with maneuvers or devices to loosen and cough up mucus, is essential. This includes, for example, 'oscillating positive expiratory pressure' (OPEP). This helps keep the lungs open and prevent infections.
This is listed in all guidelines and forms the basis of daily care.
**Exercise and physical activity**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular physical activity helps loosen mucus, improves lung function and supports overall health. This is strongly recommended in all guidelines.
Newer and experimental treatments
**GDC-6988** (inhaled)
ExperimentaliOngoing in study setting, outcome still unknown
This is a medicine under continuous investigation that is meant to improve water and salt excretion in the lungs, independent of the CFTR protein. Clinical trials are ongoing.
**ANG003**
ExperimentaliOngoing in study setting, outcome still unknown
This medicine targets inflammatory signals and is being studied to prevent lung damage.
**Microbial targets**: antiviral and anti-Staphylococcus research
ResearchediPositive results in clinical studies, not yet standard treatment
Various research groups are studying how Staphylococcus aureus and Pseudomonas aeruginosa persist in cystic fibrosis, and whether new approaches (for example small RNAs that stop bacteria) can help.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._